Gene expression markers of tumor resistance to HER2 inhibitor treatment

摘要

The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab.

主权项

1. A method of predicting the likelihood of response of a mammalian subject diagnosed with or at risk of developing a HER2 expressing tumor to treatment with a HER2 inhibitor, comprising
(a) measuring in a tumor cell sample obtained from said human subject, an identical or increased expression level of the RNA transcript or expression product of a PPM1H gene relative to the expression level of PPM1H gene in a normal cell of the same cell type, wherein the identical or increased expression level identifies the subject as not likely to be resistant to treatment with trastuzumab, and (b) treating the subject with trastuzumab.